{
  "guideline": {
    "id": "PA166104991",
    "name": "Annotation of DPWG Guideline for abacavir and HLA-B",
    "relatedChemicals": [
      {
        "id": "PA448004",
        "name": "abacavir",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA35056",
        "name": "major histocompatibility complex, class I, B",
        "symbol": "HLA-B"
      }
    ],
    "source": "DPWG",
    "recommendation": true,
    "guidelineGenes": [
      {
        "alleles": [
          {
            "id": 1451417584,
            "_label": "*57:01:01",
            "function": {
              "term": "Presence",
              "termId": "haplotypeTags:1445558333"
            }
          },
          {
            "id": 1451417600,
            "_label": "Other",
            "function": {
              "term": "Absence",
              "termId": "haplotypeTags:1445558334"
            }
          }
        ],
        "gene": {
          "chr": {
            "id": "PA532",
            "name": "chr6",
            "symbol": null
          },
          "strand": "minus",
          "id": "PA35056",
          "name": "major histocompatibility complex, class I, B",
          "symbol": "HLA-B"
        }
      }
    ],
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104991",
    "version": 30
  },
  "annotationGroups": [
    {
      "id": "PA166240522",
      "name": "*57:01 negative",
      "strength": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "rxChangeStatus": {
        "term": "No",
        "termId": "rxChange:1448602495"
      },
      "genePhenotypes": [
        "HLA-B:Absence/Absence"
      ],
      "metabolizerStatus": null,
      "recommendation": {
        "id": 1451782567,
        "html": "<p>The guideline does not provide a recommendation for abacavir in patients with no HLA-B*57:01 alleles or negative for the.HLA-B*57:01 test.</p>\n"
      },
      "implications": {
        "id": 1451782566,
        "html": "<p>The guideline does not provide a description of the impact of the absence of HLA-B*57:01 alleles on abacavir.</p>\n"
      },
      "activityScore": null
    },
    {
      "id": "PA166240523",
      "name": "*57:01 positive",
      "strength": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "rxChangeStatus": {
        "term": "Yes",
        "termId": "rxChange:1448602497"
      },
      "genePhenotypes": [
        "HLA-B:Absence/Presence",
        "HLA-B:Presence/Presence"
      ],
      "metabolizerStatus": null,
      "recommendation": {
        "id": 1451782565,
        "html": "<p>Abacavir is contra-indicated for HLA-B*57:01-positive patients.</p>\n<ol>\n<li>Avoid abacavir.</li>\n</ol>\n"
      },
      "implications": {
        "id": 1451782564,
        "html": "<p>HLA-B*57:01-positive patients have a strongly increased risk of a hypersensitivity reaction to abacavir. 48% of the HLA-B*57:01-positive patients develop a severe and potentially life-threatening hypersensitivity reaction to abacavir</p>\n"
      },
      "activityScore": null
    }
  ],
  "citations": [
    {
      "pmid": "21412232",
      "title": "Pharmacogenetics: from bench to byte--an update of guidelines.",
      "authors": [
        "Swen J J",
        "Nijenhuis M",
        "de Boer A",
        "Grandia L",
        "Maitland-van der Zee A H",
        "Mulder H",
        "Rongen G A P J M",
        "van Schaik R H N",
        "Schalekamp T",
        "Touw D J",
        "van der Weide J",
        "Wilffert B",
        "Deneer V H M",
        "Guchelaar H-J"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2011
    }
  ]
}